BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

...“We are looking at differentiation not transdifferentiation. The architecture of the cochlea is very important.” Acousia Therapeutics GmbH...
...Analytics Cord Blood Registry Otonomy Inc. Pipeline Therapeutics Inc. Novartis AG GenVec Inc. Frequency Therapeutics Inc. Astellas Pharma Inc. Audion Therapeutics B.V. Quark Pharmaceuticals Inc. Acousia Therapeutics GmbH Sound...
BioCentury | May 20, 2019
Finance

Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

...as it was conducting due diligence for a separate investment in German hearing loss play Acousia Therapeutics GmbH...
BioCentury | May 18, 2018
Financial News

Acousia raises $12M in series B

...Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) on May 14 in a...
...4, 2016) . Antz declined to disclose ACOU085's therapeutic modality or target. Acousia Therapeutics GmbH, Tübingen, Germany Jennie Walters ACOU085 Acousia Therapeutics GmbH...
BioCentury | May 14, 2018
Financial News

Acousia raises €10M in series B

...Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) in a series B round...
...see BioCentury, Jan. 4, 2016) . Antz declined to disclose ACOU085's therapeutic modality or target. Jennie Walters Acousia Therapeutics GmbH...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

...recombinant adenovirus 5 (Ad5) vector to deliver the atonal homolog 1 (ATOH1; HATH1) transcription factor. Acousia Therapeutics GmbH...
...hair cell regeneration all raised their initial round of financing within the past six years. Acousia Therapeutics GmbH...
...than $500 million in annual sales, would likely boost pharma interest. Companies and Institutions Mentioned Acousia Therapeutics GmbH...
BioCentury | Jan 6, 2017
Company News

Axxam, Acousia deal

...$2.6 million) venture round. Axxam S.p.A. , Milan, Italy Acousia Therapeutics GmbH , Tübingen, Germany Business: Other Alex Himes Acousia Therapeutics GmbH Axxam...
BioCentury | Dec 16, 2016
Financial News

Acousia completes venture financing

...by Boehringer Ingelheim Venture Fund. KfW and Axxam S.p.A. also participated. Acousia Therapeutics GmbH , Tübingen, Germany Alicia Parker Acousia Therapeutics GmbH...
BioCentury | Jan 4, 2016
Emerging Company Profile

Regrowing hearing

...on protecting sensory cells to prevent hearing loss in at-risk patients. Companies and Institutions Mentioned Acousia Therapeutics GmbH...
Items per page:
1 - 8 of 8
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

...“We are looking at differentiation not transdifferentiation. The architecture of the cochlea is very important.” Acousia Therapeutics GmbH...
...Analytics Cord Blood Registry Otonomy Inc. Pipeline Therapeutics Inc. Novartis AG GenVec Inc. Frequency Therapeutics Inc. Astellas Pharma Inc. Audion Therapeutics B.V. Quark Pharmaceuticals Inc. Acousia Therapeutics GmbH Sound...
BioCentury | May 20, 2019
Finance

Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

...as it was conducting due diligence for a separate investment in German hearing loss play Acousia Therapeutics GmbH...
BioCentury | May 18, 2018
Financial News

Acousia raises $12M in series B

...Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) on May 14 in a...
...4, 2016) . Antz declined to disclose ACOU085's therapeutic modality or target. Acousia Therapeutics GmbH, Tübingen, Germany Jennie Walters ACOU085 Acousia Therapeutics GmbH...
BioCentury | May 14, 2018
Financial News

Acousia raises €10M in series B

...Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) in a series B round...
...see BioCentury, Jan. 4, 2016) . Antz declined to disclose ACOU085's therapeutic modality or target. Jennie Walters Acousia Therapeutics GmbH...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

...recombinant adenovirus 5 (Ad5) vector to deliver the atonal homolog 1 (ATOH1; HATH1) transcription factor. Acousia Therapeutics GmbH...
...hair cell regeneration all raised their initial round of financing within the past six years. Acousia Therapeutics GmbH...
...than $500 million in annual sales, would likely boost pharma interest. Companies and Institutions Mentioned Acousia Therapeutics GmbH...
BioCentury | Jan 6, 2017
Company News

Axxam, Acousia deal

...$2.6 million) venture round. Axxam S.p.A. , Milan, Italy Acousia Therapeutics GmbH , Tübingen, Germany Business: Other Alex Himes Acousia Therapeutics GmbH Axxam...
BioCentury | Dec 16, 2016
Financial News

Acousia completes venture financing

...by Boehringer Ingelheim Venture Fund. KfW and Axxam S.p.A. also participated. Acousia Therapeutics GmbH , Tübingen, Germany Alicia Parker Acousia Therapeutics GmbH...
BioCentury | Jan 4, 2016
Emerging Company Profile

Regrowing hearing

...on protecting sensory cells to prevent hearing loss in at-risk patients. Companies and Institutions Mentioned Acousia Therapeutics GmbH...
Items per page:
1 - 8 of 8